According to a study, hospitalized COVID-19 patients who get antiplatelet and anticoagulant medications at the same time may fare better than those who receive only therapeutic anticoagulation (TAC).
 |
| Photo: Red and White Blood Cells in Artery | InStyleHealth |
The study comprised 242 patients with COVID-19
infection who were admitted to a single university hospital. TAC (n=31),
prophylactic anticoagulation plus antiplatelet (PACAP; n=95), TAC plus
antiplatelet (TACAP; n=65), and prophylactic anticoagulation (PAC; n=95) were
the four therapy groups: TAC (n=31), PACAP (n=95), TACAP (n=65), and PAC
(n=95).
Dyspnea was the major symptom in 43.4 percent of the
overall group when they were admitted. The TACAP group had the lowest oxygen
saturation levels and the most weight on average. In laboratory tests, the TAC
group had the greatest levels of D-dimer and C-reactive protein (CRP), while
the TACAP group had the highest amounts of interleukin-6.
During their hospital stay, the majority of the
patients (92.1%) were given steroids. In the meantime, 97.5 percent received
vitamin C, 64.9 percent received vitamin D, and 95.9% received zinc. Treatment
exposure subgroups had significantly varied median days of oxygen need
(p0.001).
In multivariable Cox regression models, both TACAP and
TAC were associated with lower rates of in-hospital all-cause mortality (aHR,
0.113, 95 percent confidence interval [CI], 0.028–0.449 and aHR, 0.126, 95
percent confidence interval [CI], 0.028–0.528, respectively) than PAC. In both
groups, the number of people who needed to be treated was 11.
Furthermore, when compared to PAC, PACAP had a lower
risk of invasive mechanical ventilation (aHR, 0.07, 95 percent CI,
0.014–0.351).
There were no changes in the frequency of large or
minor bleeds, ICU admission, or the composite outcome of in-hospital death, ICU
hospitalization, or mechanical ventilation need.
Source: Open Heart 2021;8:e001785